23andMe Holding Co. (ME)
| Previous close | 4.6500 |
| Open | 4.6350 |
| Bid | 4.4600 x 1000 |
| Ask | 4.4700 x 1200 |
| Day's range | 4.4000 - 4.6500 |
| 52-week range | 4.4000 - 18.1600 |
| Volume | |
| Avg. volume | 3,119,582 |
| Market cap | 2.055B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program
GSK extends exclusive target discovery period of collaboration for a fifth year to discover and validate novel drug targets using 23andMe’s proprietary genetic and health survey database 23andMe elects for royalty option as GSK advances immuno-oncology antibody collaboration program targeting CD96 into development Company will discuss at its R&D Day event today at 8:00 a.m. Pacific Time SUNNYVALE, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading c
- GlobeNewswire
23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker
The clearance allows 23andMe to report on the G84E mutation in the HOXB13 gene, clinically shown to significantly increase the risk of developing prostate cancer in men with the mutationSUNNYVALE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today received FDA clearance for a genetic health risk report on a hereditary prostate cancer marker. This is the Company’s third cancer risk report clearance, follo
- GlobeNewswire
23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors
23ME-00610 targets CD200R1, an important regulator of T cells and myeloid cells CD200R1 was identified as a promising immuno-oncology target through 23andMe’s proprietary genetic and health survey database Company will host a virtual R&D Day event on January 18, 2022 SUNNYVALE, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced the first participant has been dosed in a Phase 1 clinical trial ev
